The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 1× · see citing works

A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C

Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406 · see citing works

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,805 · see citing works

Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies

D’Amico, G., García–Tsao, G., & Pagliaro, L. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 3,195 · see citing works

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · see citing works

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,416 · see citing works

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · see citing works

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · see citing works

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis

García–Tsao, G., Sanyal, A. J., Grace, N. D., & Carey, W. (2007) · Hepatology · doi:10.1002/hep.21907 · Cited by 1,714 · see citing works

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

Younossi, Z. M., Blissett, D. B., Blissett, R., Henry, L. L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,289 · see citing works

Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis

Ripoll, C., Groszmann, R., Garcia–Tsao, G., Grace, N., Burroughs, A., Planas, R., Escorsell, A., Garcia–Pagan, J. C., Makuch, R., Patch, D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.024 · Cited by 1,183 · see citing works

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

Charlton, M., Burns, J. M., Pedersen, R. A., Watt, K. D. S., Heimbach, J. K., & Dierkhising, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.061 · Cited by 1,103 · see citing works

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067 · see citing works

Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study

Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806 · see citing works

The clinical use of HVPG measurements in chronic liver disease

Bosch, J., Abraldeṣ, J. G., Berzigotti, A., & García‐Pagán, J. C. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.149 · Cited by 732 · see citing works

Use of Liver Imaging and Biopsy in Clinical Practice

Tapper, E. B., & Lok, A. S.-F. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1610570 · Cited by 452 · see citing works

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

Bhala, N. B., Angulo, P., van der Poorten, D., Lee, E., Hui, J. M., Saracco, G. M., Adams, L. A., Charatcharoenwitthaya, P., Topping, J. H., Bugianesi, E., et al. (2011) · Hepatology · doi:10.1002/hep.24491 · Cited by 450 · see citing works

NAFLD and liver transplantation: Current burden and expected challenges

Pais, R., Barritt, A. S., Calmus, Y., Scatton, O., Runge, T. M., Lebray, P., Poynard, T., Ratziu, V., & Conti, F. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.033 · Cited by 429 · see citing works

Evaluating Prediction Rules for <i>t</i> -Year Survivors With Censored Regression Models

Uno, H., Cai, T., Tian, L., & Wei, L. J. (2007) · Journal of the American Statistical Association · doi:10.1198/016214507000000149 · Cited by 413 · see citing works

Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis C

Vergniol, J., Foucher, J., Terrebonne, É., Bernard, P., Bail, B. L., Merrouche, W., Couzigou, P., & de Lédinghen, V. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.058 · Cited by 411 · see citing works

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

Harrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.006 · Cited by 384 · see citing works

Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data

Kabbany, M. N., Selvakumar, P. K. C., Watt, K. D. S., López, R., Akras, Z., Zein, N. N., Carey, W., & Alkhouri, N. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.5 · Cited by 241 · see citing works

Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016

Kaswala, D. H., Lai, M., & Afdhal, N. H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4079-4 · Cited by 155 · see citing works

The clinical and economic burden of NAFLD: time to turn the tide

Abdelmalek, M. F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.178 · Cited by 16 · see citing works

Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis

Ratziu, V., Sanyal, A. J., Torres, D., Hinrichsen, H. M., Serfaty, L., Bambha, K. M., Jayakumar, S., Goodman, Z., Abdelmalek, M. F., Aguilar, R., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)31616-1 · Cited by 4 · see citing works

Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis

Bosch, J., Harrison, S. A., Ratziu, V., Shiffman, M. L., Diehl, A. M., Caldwell, S. H., Rockey, D. C., Ghalib, R. H., Thuluvath, P. J., Abdelmalek, M. F., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30593-7 · Cited by 2 · see citing works

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

Mechanisms and disease consequences of nonalcoholic fatty liver disease

Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002 · see citing works

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925 · see citing works

Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

Cotter, T. G., & Rinella, M. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,205 · see citing works

NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes

Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology &amp; Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643 · see citing works

Complications, morbidity and mortality of nonalcoholic fatty liver disease

Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C. D., & Targher, G. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154170 · Cited by 558 · see citing works

Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus

Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 507 · see citing works

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.027 · Cited by 497 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

Davison, B. A., Harrison, S. A., Cotter, G., Alkhouri, N., Sanyal, A., Edwards, C., Colca, J. R., Iwashita, J., Koch, G. G., & Dittrich, H. C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.025 · Cited by 448 · see citing works

Role of liver sinusoidal endothelial cells in liver diseases

Gracia‐Sancho, J., Caparrós, E., Fernández‐Iglesias, A., & Francés, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00411-3 · Cited by 425 · see citing works

Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review

Lee, J., Vali, Y., Boursier, J., Spijker, R., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2020) · Liver International · doi:10.1111/liv.14669 · Cited by 385 · see citing works

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 370 · see citing works

AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review

Loomba, R. S., Lim, J. K., Patton, H. M., & El‐Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.053 · Cited by 360 · see citing works

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association

Cusi, K. J., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 396 · see citing works

Advances in non-invasive assessment of hepatic fibrosis

Loomba, R. S., & Adams, L. A. (2020) · Gut · doi:10.1136/gutjnl-2018-317593 · Cited by 351 · see citing works

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Patel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W., Greenbloom, S., Jayakumar, S., et al. (2020) · Hepatology · doi:10.1002/hep.31205 · Cited by 347 · see citing works

Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population

Graupera, I., Thiele, M. S., Serra‐Burriel, M., Caballería, L., Roulot, D. M., Wong, G. L., Fabrellas, N., Guha, I. N., Arslanow, A., Expósito, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.034 · Cited by 302 · see citing works

Natural history and progression of metabolic dysfunction-associated steatotic liver disease

Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology &amp; Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310 · see citing works

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Loomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., et al. (2021) · Hepatology · doi:10.1002/hep.31622 · Cited by 296 · see citing works

Therapeutic pipeline in nonalcoholic steatohepatitis

Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278 · see citing works

Non-alcoholic fatty liver disease: A patient guideline

Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264 · see citing works

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study

Harrison, S. A., Ratziu, V., Boursier, J., Francque, S., Bédossa, P., Majd, Z., Cordonnier, G., Sudrik, F. B., Darteil, R., Liebe, R., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30252-1 · Cited by 258 · see citing works

Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050

Le, P., Tatar, M., Dasarathy, S., Alkhouri, N., Herman, W. H., Taksler, G. B., Deshpande, A., Ye, W., Adekunle, O. A., McCullough, A. J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.54707 · Cited by 261 · see citing works

Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults

Tilg, H., Petta, S., Stefan, N., & Targher, G. (2025) · JAMA · doi:10.1001/jama.2025.19615 · Cited by 274 · see citing works

Natural history of metabolic dysfunction-associated steatotic liver disease

Lekakis, V., & Papatheodoridis, G. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.11.005 · Cited by 243 · see citing works

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Hassanein, T., Kohli, A., Huss, R. S., Zhu, Y., Billin, A. N., Damgaard, L. H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.003 · Cited by 230 · see citing works

Impact of non-invasive biomarkers on hepatology practice: past, present and future

Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224 · see citing works

Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma

Younossi, Z. M., & Henry, L. L. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100305 · Cited by 218 · see citing works

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Tan, Z., Sun, H., Xue, T., Gan, C., Liu, H., Xie, Y., Yao, Y., & Ye, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.730176 · Cited by 220 · see citing works

Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

Henry, L. L., Paik, J. M., & Younossi, Z. M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17158 · Cited by 217 · see citing works

MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis

Noureddin, M., Truong, E., GORNBEIN, J. A., Saouaf, R., Guindi, M. M., Todo, T., Noureddin, N., Yang, J. D., Harrison, S. A., & Alkhouri, N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.012 · Cited by 207 · see citing works

Novel therapeutic targets for cholestatic and fatty liver disease

Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204 · see citing works

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH

Taylor-Weiner, A. N., Pokkalla, H., Han, L., Jia, C., Huss, R. S., Chung, C., Elliott, H. L., Glass, B., Pethia, K., Carrasco‐Zevallos, O. M., et al. (2021) · Hepatology · doi:10.1002/hep.31750 · Cited by 194 · see citing works

Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

Loomba, R. S., Wong, R. J., Fraysse, J., Shreay, S., Li, S., Harrison, S. A., & Gordon, S. C. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15679 · Cited by 187 · see citing works

Management of non-alcoholic fatty liver disease

Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 181 · see citing works

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology · doi:10.1002/hep.32204 · Cited by 171 · see citing works

Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Tincopa, M. A., & Loomba, R. S. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00066-3 · Cited by 163 · see citing works

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy

Mandorfer, M., Kozbial, K., Schwabl, P., Chromy, D., Semmler, G., Stättermayer, A. F., Pinter, M., Hernández–Gea, V., Fritzer‐Szekeres, M., Steindl‐Munda, P., et al. (2019) · Hepatology · doi:10.1002/hep.30885 · Cited by 161 · see citing works

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

García–Tsao, G., Bosch, J., Kayali, Z., Harrison, S. A., Abdelmalek, M. F., Lawitz, E., Satapathy, S. K., Ghabril, M., Shiffman, M. L., Younes, Z. H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.010 · Cited by 158 · see citing works

The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH

Loomba, R. S., & Adams, L. A. (2019) · Hepatology · doi:10.1002/hep.30946 · Cited by 151 · see citing works

Noninvasive assessment of liver fibrosis in NAFLD

Sanyal, A. J., Castera, L., & Wong, V. W.-S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.042 · Cited by 157 · see citing works

Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options

Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 152 · see citing works

Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants

Ajmera, V. H., Kim, B. K., Yang, K. Y., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., Nakajima, A., Idılman, R., Gümüşsoy, M., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.073 · Cited by 139 · see citing works

The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis

Reiberger, T. (2021) · Hepatology Communications · doi:10.1002/hep4.1855 · Cited by 137 · see citing works

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

Noureddin, M., Rinella, M. E., Chalasani, N., Neff, G. W., Lucas, K. J., Rodriguez, M. E., Rudraraju, M., Patil, R., Behling, C. A., Burch, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502242 · Cited by 144 · see citing works

Breakthroughs in therapies for NASH and remaining challenges

Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132 · see citing works

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

Sanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Sheikh, M. Y., Trotter, J. F., Knapple, W., Lawitz, E. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.014 · Cited by 137 · see citing works

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC

Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 130 · see citing works

Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design

Allen, A. M., Therneau, T. M., Ahmed, O. T., Gidener, T., Mara, K. C., Larson, J. J., Canning, R. E., Benson, J. T., & Kamath, P. S. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.004 · Cited by 124 · see citing works

Recent Epidemiology of Nonalcoholic Fatty Liver Disease

Murag, S., Ahmed, A., & Kim, D. (2020) · Gut and Liver · doi:10.5009/gnl20127 · Cited by 121 · see citing works

Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis

Ferrusquía‐Acosta, J., Bassegoda, O., Turco, L., Reverter, E., Pellone, M., Bianchini, M., Pérez‐Campuzano, V., Ripoll, E., García‐Criado, Á., Graupera, I., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.10.003 · Cited by 123 · see citing works

Poor Awareness of Liver Disease Among Adults With NAFLD in the United States

Alqahtani, S. A., Paik, J. M., Biswas, R., Arshad, T., Henry, L. L., & Younossi, Z. M. (2021) · Hepatology Communications · doi:10.1002/hep4.1765 · Cited by 120 · see citing works

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Loomba, R. S., Morgan, E. S., Watts, L. M., Xia, S., Hannan, L. A., Geary, R. S., Baker, B. F., & Bhanot, S. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30186-2 · Cited by 117 · see citing works

Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH

Naoumov, N. V., Brees, D., Loeffler, J., Chng, E., Ren, Y., Lopez, P., Tai, D., Lamle, S., & Sanyal, A. J. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.018 · Cited by 115 · see citing works

Noninvasive Assessment of Liver Fibrosis

Castéra, L., Rinella, M. E., & Tsochatzis, E. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2403308 · Cited by 115 · see citing works

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Loomba, R. S., Sanyal, A. J., Nakajima, A., Neuschwander‐Tetri, B. A., Goodman, Z. D., Harrison, S. A., Lawitz, E., Gunn, N., Imajo, K., Ravendhran, N., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.011 · Cited by 111 · see citing works

Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease

Bassegoda, O., Olivas, P., Turco, L., Mandorfer, M., Serra‐Burriel, M., Téllez, L., Kwanten, W. J., Laroyenne, A., Nicoară-Farcău, O., Alvarado‐Tápias, E., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.10.023 · Cited by 111 · see citing works

ROS/RNS as molecular signatures of chronic liver diseases

Che, Z., Zhou, Z., Li, S.-Q., Gao, L., Xiao, J., & Wong, N.-K. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.001 · Cited by 110 · see citing works

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study

Harrison, S. A., Frías, J. P., Lucas, K. J., Reiss, G. M., Neff, G. W., Bollepalli, S., Su, Y., Chan, D. C., Tillman, E. J., Moulton, A. W., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.02.022 · Cited by 106 · see citing works

Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025

Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 102 · see citing works

Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives

Dai, X.-M., Feng, J., Chen, Y., Huang, S., Shi, X., Liu, X., & Sun, Y. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00469-4 · Cited by 96 · see citing works

A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis

Rinella, M. E., Lieu, H. D., Kowdley, K. V., Goodman, Z. D., Alkhouri, N., Lawitz, E., Ratziu, V., Abdelmalek, M. F., Wong, V. W., Younes, Z. H., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000607 · Cited by 99 · see citing works

From the origin of NASH to the future of metabolic fatty liver disease

Geier, A., TINIAKOS, D. G., Denk, H., & Trauner, M. A. (2021) · Gut · doi:10.1136/gutjnl-2020-323202 · Cited by 90 · see citing works

Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions

Ciardullo, S., Muraca, E., Vergani, M., Invernizzi, P., & Perseghin, G. (2023) · Gastroenterology report · doi:10.1093/gastro/goae029 · Cited by 90 · see citing works

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

Luo, Y., Wadhawan, S., Greenfield, A., Decato, B. E., Oseini, A. M., Collen, R., Shevell, D. E., Thompson, J., Jarai, G., Charles, E. D., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1670 · Cited by 87 · see citing works

New Drugs for Hepatic Fibrosis

Shan, L., Wang, F., Zhai, D., Meng, X., Liu, J., & Lv, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.874408 · Cited by 85 · see citing works

NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study

Harrison, S. A., Ratziu, V., Magnanensi, J., Hajji, Y., Deledicque, S., Majd, Z., Rosenquist, C., Hum, D. W., Staels, B., Anstee, Q. M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.031 · Cited by 80 · see citing works

Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action

Younossi, Z. M., & Henry, L. L. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0010 · Cited by 83 · see citing works

Fatty Liver Disease: Diagnosis and Stratification

Saiman, Y., Duarte‐Rojo, A., & Rinella, M. E. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-020407 · Cited by 78 · see citing works

Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD

Paternostro, R., Kwanten, W. J., Hofer, B., Semmler, G., Bagdadi, A., Luzko, I., Hernández–Gea, V., Graupera, I., García‐Pagán, J. C., Saltini, D., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.033 · Cited by 77 · see citing works

Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?

Baffy, G., & Bosch, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.029 · Cited by 69 · see citing works

Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach

Grgurević, I., Podrug, K., Mikolašević, I., Kukla, M., Madir, A., & Tsochatzis, E. A. (2020) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2020/9181368 · Cited by 68 · see citing works

Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD

Gawrieh, S., Sethunath, D., Cummings, O. W., Kleiner, D. E., Vuppalanchi, R., Chalasani, N., & Tüceryan, M. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151518 · Cited by 68 · see citing works

Established and emerging factors affecting the progression of nonalcoholic fatty liver disease

Kechagias, S., Nasr, P., Blomdahl, J., & Ekstedt, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154183 · Cited by 69 · see citing works

A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis

Bosch, J., Chung, C., Carrasco‐Zevallos, O. M., Harrison, S. A., Abdelmalek, M. F., Shiffman, M. L., Rockey, D. C., Shanis, Z., Juyal, D., Pokkalla, H., et al. (2021) · Hepatology · doi:10.1002/hep.32087 · Cited by 65 · see citing works

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

Frenette, C. T., Kayali, Z., Mena, E., Mantry, P., Lucas, K. J., Neff, G. W., Rodriguez, M., Thuluvath, P. J., Weinberg, E. M., Bhandari, B. R., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.029 · Cited by 62 · see citing works

Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa

Spearman, C. W., Afihene, M., Betiku, O., Bobat, B., Cunha, L., Kassianides, C., Katsidzira, L., Desalegn, H., Ocama, P., Ojo, O., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00275-2 · Cited by 61 · see citing works

Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma

Talamantes, S., Lisjak, M., Gilglioni, E. H., Llamoza-Torres, C. J., Ramos‐Molina, B., & Gurzov, E. N. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100811 · Cited by 60 · see citing works

KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease

Kim, M. N., Han, J. W., An, J., Kim, B. K., Jin, Y., Kim, S., Lee, M., Lee, H. A., Cho, Y., Kim, H. Y., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0506 · Cited by 62 · see citing works

Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non‐alcoholic steatohepatitis

Guerra, S., Mocciaro, G., & Gastaldelli, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13695 · Cited by 60 · see citing works

New aspects of hepatic endothelial cells in physiology and nonalcoholic fatty liver disease

Sun, X., & Harris, E. N. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00062.2020 · Cited by 58 · see citing works

Epigenetic Regulation of Kupffer Cell Function in Health and Disease

Bennett, H., Troutman, T. D., Sakai, M., & Glass, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609618 · Cited by 66 · see citing works

Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease

Canbay, A. E., Kachru, N., Haas, J. S., Sowa, J., Meise, D., & Ozbay, A. B. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16016 · Cited by 56 · see citing works

Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis

Wang, M., Li, L., Xu, Y., Du, J., & Ling, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958428 · Cited by 56 · see citing works

The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population

Hu, H., Han, Y. Y., Cao, C., & He, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03611-4 · Cited by 53 · see citing works

Old age as a risk factor for liver diseases: Modern therapeutic approaches

Georgieva, M., Xenodochidis, C., & Krasteva, N. A. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112334 · Cited by 56 · see citing works

AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases

Iyer, J. S., Juyal, D., Le, Q., Shanis, Z., Pokkalla, H., Pouryahya, M., Pedawi, A., Stanford-Moore, S. A., Biddle-Snead, C., Carrasco-Zevallos, O., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03172-7 · Cited by 54 · see citing works

The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank

Hydes, T., Kennedy, O. J., Buchanan, R. M., Cuthbertson, D. J., Parkes, J., Fraser, S. D., & Roderick, P. J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02891-x · Cited by 52 · see citing works

Prevention of First Decompensation in Advanced Chronic Liver Disease

Mandorfer, M., & Simbrunner, B. (2021) · Clinics in Liver Disease · doi:10.1016/j.cld.2021.01.003 · Cited by 49 · see citing works

Metabolic associated fatty liver disease: Addressing a new era in liver transplantation

Gill, M. G., & Majumdar, A. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i12.1168 · Cited by 48 · see citing works

Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial

Vijayaraghavan, R., Jindal, A., Arora, V., Choudhury, A. K., Kumar, G., & Sarin, S. K. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000551 · Cited by 46 · see citing works

Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis

Are, V. S., Vuppalanchi, R., Vilar‐Gómez, E., & Chalasani, N. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.070 · Cited by 46 · see citing works

Natural History of NAFLD

Pais, R., & Maurel, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061161 · Cited by 46 · see citing works

Obesity, obesities and gastrointestinal cancers

Zou, Y., & Pitchumoni, C. S. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101592 · Cited by 44 · see citing works

AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension

Sterling, R. K., Asrani, S. K., Levine, D., Duarte‐Rojo, A., Patel, K., Fiel, M. I., Leung, D. H., Taouli, B. A., Alsawas, M., Murad, M. H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000844 · Cited by 47 · see citing works

Inflammation in MASLD progression and cancer

Kim, Y., Park, Y., Rho, H., Yao, T., Gao, B., & Hwang, S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101414 · Cited by 61 · see citing works

Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update

Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 43 · see citing works

Rectifying disorder of extracellular matrix to suppress urethral stricture by protein nanofilm-controlled drug delivery from urinary catheter

Tian, J., Fu, D., Liu, Y., Guan, Y., Miao, S., Xue, Y., Chen, K., Huang, S., Zhang, Y., Xue, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38282-2 · Cited by 43 · see citing works

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology · doi:10.1002/hep.32204 · Cited by 171 · see citing works

The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis

Younossi, Z. M., Anstee, Q. M., Wai-Sun Wong, V., Trauner, M., Lawitz, E. J., Harrison, S. A., Camargo, M., Kersey, K., Subramanian, G. M., Myers, R. P., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.003 · Cited by 118 · see citing works

1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)

Sanyal, A. J., Abdelmalek, M. F., Caldwell, S. H., Shiffman, M. L., Ghalib, R. H., Lawitz, E., Jiang, D., Schall, R. A., Mccolgan, B., Myers, R., et al. (2019) · Diabetes · doi:10.2337/db19-1876-p

The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH

Loomba, R. S., & Adams, L. A. (2019) · Hepatology · doi:10.1002/hep.30946 · Cited by 151 · see citing works

Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis

Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S. H., Shiffman, M. L., Aguilar, R., Jia, C., Mccolgan, B., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30267-2 · Cited by 10 · see citing works